Key facts
- It has raised $1.7M; the latest was Early Stage VC in May 2024.
- Notable investors include Nissay Capital, Intellectual Property Acceleration Program for Startups, SG Incubate, JMTC Capital, Mirai Souzou Investments — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for NOVIGO (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for NOVIGO (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NOVIGO (Drug Discovery)
Operator of transdermal drug development and cosmetic development company intended to improve quality of life. The company develops drugs using transdermal formulations, drug development using modern technology, and cosmetic development, enabling the healthcare industry to access the next generation of transdermal products.
- Sector
- Healthcare
- HQ
- Fukuoka, Japan
- Founded
- 2021
- Employees
- 8
- Website
- novigopharma.co.jp/
- Ownership
- Privately Held (backing)
NOVIGO (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NOVIGO (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NOVIGO (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.